Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 7 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 12077605

    Cysteine protease inhibitors and methods of use thereof

    Anixa Biosciences, Inc. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  2. US 12077515

    Selective histone deacetylase inhibitors for the treatment of human disease

    Shuttle Pharmaceuticals, Inc. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  3. US 12077506

    Indane derivatives as hypoxia inducible factor-2(α) inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  4. US 12071428

    Indazole compounds as kinase inhibitors

    TYRA BIOSCIENCES, INC. · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  5. US 12070460

    Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  6. US 12071411

    Inhibitors of HIF-2α and methods of use thereof

    Arcus Biosciences, Inc. · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  7. US 12065448

    Heteroaryl plasma kallikrein inhibitors

    Takeda Pharmaceutical Company Limited · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  8. US 12060346

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted
  9. US 12060396

    Fused in sarcoma (FUS) nuclear translocation inhibitors for preventing fibrosis

    THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted
  10. US 12060362

    Inhibitors of glucose transporters (GLUTs)

    Lead Discovery Center GmbH · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted
  11. US 12059418

    Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted
  12. US 12060555

    MicroRNA-33 inhibitors and use thereof in the treatment of pulmonary fibrosis

    UNIVERSITY OF CONNECTICUT · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted
  13. US 12054500

    Arginase inhibitors

    Arcus Biosciences, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  14. US 12054475

    Substituted heterocycles as aldehyde dehydrogenase inhibitors

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  15. US 12054492

    Imidazole-containing inhibitors of ALK2 kinase

    BioCryst Pharmaceuticals, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  16. US 12054483

    Small molecule inhibitors of DYRK/CLK and uses thereof

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  17. US 12048749

    C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

    Revolution Medicines, Inc. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  18. US 12043629

    RIP1K inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  19. US 12042543

    Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2

    Northwestern University · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  20. US 12043607

    HDAC inhibitors and therapeutic use thereof

    Tango Therapeutics, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  21. US 12043610

    Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  22. US 12042487

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  23. US 12043640

    Prodrugs of STAT3 inhibitors

    Tvardi Therapeutics, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  24. US 12030897

    Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof

    Medshine Discovery Inc. · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted